Slides
Page 1
AlloHeme : Advancing AI-Enabled Relapse Monitoring in AML & MDS Post-Cell Therapy Positioning CareDx to lead in precision medicine for cell therapy Investor Webcast February 12, 2026
Page 2
These slides and the accompanying oral presentation contain forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the future business plans and objectives, potential growth opportunities, competitive position, industry environment and potential market opportunities of CareDx®, Inc. (together with its subsidiaries, “CareDx” or the “Company”), CareDx’s ability to generate revenue and increase the commercial success of its current and future testing services, products and patient and digital solutions, and the outcome or success of CareDx’s clinical trial collaborations and registry studies, are forward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “target,” “contemplate,” “predict,” “expect,” and the negative and plural forms of these words and similar expressions are intended to identify that CareDx has based these forward-looking statements on its own estimates and assumptions and its current expectations and projections about future events. These forward- looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx's control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx's filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 filed by CareDx with the SEC on November 4, 2025, and other reports that CareDx has filed with the SEC. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. CareDx undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this presentation or to conform these statements to actual results or to changes in CareDx’s expectations. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company. 2 Safe Harbor Statement
Page 3
3 John Hanna President & Chief Executive Officer
Page 4
Our Vision A world where every patient receives the transplant they need to live longer, fuller lives. Our Mission Create life-changing solutions that enable transplant patients to thrive.
Page 5
200K+ NGS-based HLA typing kits sold annually XX% 1M+ Molecular tests performed to monitor for organ rejection 70% of US transplant centers use at least one CareDx software solution 150K+ Transplant prescriptions filled annually 25 years of transplant technology innovation Our Solutions Transform the Care of Transplant Patients
Page 6
6 CareDx is the Market Leader in Solid Organ Transplant IVD Kits, software & patient solutions, and testing services across the care continuum Source: https://srtr.transplant.hrsa.gov, total National transplants per organ in 2025 Liver LungHeart Multi-Organ CareDx Services Over 200 Solid Organ Transplant Centers Across the U.S. ~28,000 ~12,500 ~4,600 ~3,500 ~860 Kidney Transplants Annually
Page 7
7 Opportunity for CareDx to be first-to-market and take a leading role in shaping the diagnostic paradigm in this space Care delivered by a concentrated group of highly specialized cell transplant and cell therapy centers High-cost care pathways, with many patients having received cumulative treatments and procedures exceeding one million dollars High-severity hematologic malignancies where diagnostic insight can inform critical, time-sensitive treatment decisions First to marketConcentrated and specialized care settingsHigh cost of careHigh-acuity patient population The Next Frontier for CareDx: Cell Therapy
Page 8
8 Monitoring Solutions for Two Cell Therapy Modalities CareDx’s first Transplant+ indications are fast-growing and complex care settings Allogeneic HCT • Treat with systemic chemotherapy to eliminate diseased cells • HLA-matched donor stem cell infused to repopulate bone marrow • Requires long-term, intensive monitoring CAR-T Cell Therapy • Collect and genetically modify patient’s own T-cells with the Chimeric Antigen Receptor (CAR) to target cancer cells • Treat with systemic chemotherapy and then re-infuse CAR-T cells into the patient and intensively monitor
Page 9
0 2,500 5,000 7,500 10,000 12,500 15,000 17,500 20,000 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Patients Year Allogeneic HCT CAR-T Leukemias (AML, MDS, ALL) 43,000 patients Multiple Myeloma 36,000 patients Large B-Cell Lymphoma (DLBCL) 24,000 patients Expected Continued Growth in Allogeneic HCT & CAR -T Cell Therapy is a Growing Market CareDx Transplant+ solutions for cell therapy address a significant and expanding share of the hematology market Reference: Approximate annual U.S. incidence based on SEER and American Cancer Society estimates Transplants calculated using CIBMTR 2024 Annual Report (Released in Apr 2025) and Company estimate (data on file) Forecast (2024-2028) 32% CAGR 9% CAGR Allogeneic HCT Annual Patient Diagnoses by Hematologic Sub -Type CAR-T
Page 10
Addressing Critical Unmet Needs in Cell Therapy Designed to monitor relapse and therapeutic efficacy in patients undergoing HCT & CAR -T DLBCL Diffuse Large B-Cell Lymphoma B MM Multiple Myeloma ALL Acute Lymphoblastic Leukemia AML Acute Myeloid Leukemias AlloHeme Cancer Relapse Detection Existing Commercial MRD Solutions CAR-T Therapy PersistenceMonitoring ~200 Bone Marrow Transplant Centers Perform HCT and CAR -T Infusion in the U.S. MDS Myelodysplastic Syndromes Source: https://accredited.factglobal.org total HCT and CAR-T infusions performed as of January 2026
Page 11
AlloHeme: a Novel Monitoring Test for Cancer Relapse Prediction Post-Allogeneic HCT for AML/ MDS Patients Peripheral blood sample Leverages NGS technology to measure micro changes in cell populations Proprietary AI algorithm incorporates longitudinal data from whole blood and cell lineage to predict relapse Provides a Positive or Negative result for relapse similar to minimal residual disease tests
Page 12
12 Jeff Teuteberg, MD Chief Medical Officer
Page 13
AML and MDS patients need relapse surveillance post-HCT Surveillance Diagnosis Induction therapy Allogeneic Transplant Consolidation Therapy Surveillance & relapse monitoring Patient diagnosed and risk stratified Goal of achieving complete remission Patients are monitored for 1- 2 yrs by transplant center (Relapse, GVHD, Infection) Additional chemo and/or targeted Tx Donor selection, conditioning regimen prior to transplant, and GVHD Prophylaxis Managed by Hem/Onc transplant specialists at accredited HCT centers HCT: Hematopoietic cell transplantation, https://pubmed.ncbi.nlm.nih.gov/40398621/
Page 14
14 Frequent surveillance & relapse monitoring post allogeneic transplant for 1-2 years Frequent monitoring for: • Engraftment • Acute GVHD • Infection complications • Early relapse Transplant physician monitors for: • Chronic GVHD • Infection • Relapse HCT Month 1 Month 6 Year 1 Year 2Year 1.5 Shared Care with Primary Hematologist -2yrTransplant Center Follow Up -1yr
Page 15
15 Current Tool Limitations in Universal Relapse Monitoring AlloHeme provides a non-invasive, universal, and sensitive detection platform STR-PCR = Short Tandem Repeat Polymerase Chain Reaction; MFC = Multicolor Flow Cytometry; qPCR = Quantitative Polymerase Chain Reaction; NGS = Next-Generation Sequencing; BM = Bone Marrow; MFC-MRD = Multicolor Flow Cytometry–Based Measurable Residual Disease Chimerism (STR-PCR) MRD (MFC, qPCR, NGS) AlloHeme Sensitivity for Relapse Detection Lower sensitivity for relapse detection (used to measure engraftment) Low for MFC-MRD ✓ High Sensitivity Invasiveness Often require BM sample Often require BM sample ✓ Non-invasive (Blood) Universal Applicability Universal qPCR, NGS not universal ✓ Universal
Page 16
16 Dr. Ran Reshef, MD, MSc Professor of Medicine at Columbia University and Director of Translational Research,Blood and Marrow Transplantation Programat Herbert Irving Comprehensive Cancer Center
Page 17
Acrobat Results: Peripheral Blood-Based AlloHeme Test Enables Robust Relapse Surveillance in Post-HCT AML and MDS Patients • Ran Reshef1*, Stefan Ciurea2*, Ronald Sobecks3, Iskra Pusic4, Nelli Bejanyan5, Sagar S. Patel6, Arpita Gandhi7, Vamsi Kota8, Nabeel Rajeh9, Piyanuch Kongtim2, Jing Shi10, Yi Fu10, Natali Gulbahce10, Nishant Dwivedi10, Monzr M. Al Malki11#and Corey Cutler12# 1Columbia University Herbert Irving Comprehensive Cancer Center, New Y ork, NY; 2Chao Family Comprehensive Cancer Center, University of California, Irvine, CA; 3Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; 4Washington University School of Medicine, St. Louis, MO; 5Moffitt Cancer Center, Tampa, FL; 6Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 7Knight Cancer Institute, Oregon Health and Science University, Portland, OR; 8Georgia Cancer Center, Augusta University, Augusta, GA; 9Saint Louis University School of Medicine, St. Louis, MO; 10CareDx, Inc., Brisbane, CA; 11City of Hope National Medical Center, Duarte, CA; 12Dana Farber Cancer Institute, Boston, MA (2-Year Analysis) *Co-first authors; # Co-senior authors.
Page 18
Relapse Monitoring After Allo-HCT: Persistent Challenges in Improving Survival Outcomes Relapse remains the main cause of death at or beyond 100 days post -transplant1 STR-PCR MFC qPCR/dPCR NGS Sensitivity 1-5% ~10⁻³–10⁻⁴ ~10⁻⁴–10⁻⁶ ~10⁻⁴–10⁻⁶ Advantage Universal post-HCT; useful for engraftment Rapid; widely available; works without molecular targets High sensitivity for validated targets Broad coverage; detects multiple mutations; clonal evolution Disadvantage Not leukemia- specific; lower sensitivity Operator dependent, cannot be harmonized Requires a known target; only useful for distinct patient subsets. Complex, not universal, requires further standardization Tissue BM or blood Mostly BM BM or blood BM or blood Existing MRD tools have limitations for Universal Relapse Monitoring2,3 1) Spellman SR, et al . Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR. Tr ansplant Cell Ther. 2025 2) Haaksma LH et.al., Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges. Leukemia & Lymphoma. 2025 3) Blouin and Askar, Chimerism analysis for clinicians: a review of the literature and worldwide practices BMT 2022 Abbreviations: Allo-HCT: Allogeneic Hematopoietic Cell Transplant, GVHD: Graft vs. Host Disease,MRD: Measurable Residual Disease, STR -PCR: Short Tandem Repeat - Polymerase Chain Reaction, MFC: Multiparametric Flow Cytometry, qPCR: Quantitative Polymerase Chain Reaction, dPCR: Digital Polymerase Chain Reaction, NGS: Next Generation Sequencing, BM: Bone Marrow.
Page 19
ACROBAT Study Design: Prospective observational study to evaluate AlloHeme performance Number of Patients Study Overview Schedule of AlloHeme Assessments • 285 enrolled patients received HCT (AML -162; MDS-65; ALL-58) between Oct 2021 and Oct 2023 across 11 US sites • Prospective observational cohort study to evaluate AlloHeme performance to detect relapse in patients with hematologic malignancies (AML, ALL and MDS) Bi-weekly testing From month 1-3 Quarterly testing from Month 9-24 Monthly testing From month 4-6 1mo. 1.5m 2m 2.5m 3m 4m 5m 6m HCT 9m 12m 18m15m 21m 24m 19
Page 20
ACROBAT Study: AML+MDS Cohort AML + MDS Cohort 227 subjects enrolled Analytical Cohort 198 subjects included 40 Relapsed 118 Completed 2-yr Follow-up 29 subjects excluded for early events / inadequate testing by Day 49, precluding AlloHeme results: 14 Withdrew or lost to follow-up 26 Non- Relapse Mortality (NRM) • 4 subjects with early relapse • 4 subjects with early NRM • 4 subjects with early withdrawals • 17 subjects with no or only 1 test Patient Disposition
Page 21
Landmark analyses at 2, 3, and 6 months showed that the subjects positive for AlloHeme are at increased risk for post-HCT relapse 3 months post HCT 6 months post HCT HR = 6.3 (95%CI: 2.6-15.4) HR = 11.9 (95%CI: 5.0-28.2) The AlloHeme+ group comprises all subjects who were AlloHeme Test- positive at or before the landmark time points (2, 3 or 6 months). HR = 5.9 (95%CI: 2.1-16.8) 2 months post HCT
Page 22
HR = 6.2 (95%CI: 3.1-12.4) Landmark analyses at 2, 3, and 6 months showed that the subjects positive for AlloHeme are at increased risk for post -HCT relapse or death HR = 5.2 (95%CI: 2.5-11.2) 3 months post HCT 6 months post HCT2 months post HCT HR = 4.1 (95%CI: 1.7-9.6) The AlloHeme+ group comprises all subjects who were AlloHeme Test- positive at or before the landmark time points (2, 3 or 6 months).
Page 23
AlloHeme Assay Performance Performance Cohort Characterization: • ≥2 valid AlloHeme tests • Excluding NRM and Withdrawals, Total Subjects n=158 (AML, n=114 and MDS, n=44) • Based on a median of 11 tests/patient vs recommended 14 tests in the protocol • Subjects with the “disease not evaluated” status during the last (24-month) status are considered “Non- Relapsed” for the analysis Relapse No Relapse AlloHeme positive 34 9 AlloHeme negative 6 109 Test Performance 85% Sensitivity 92% Specificity 95% NPV 79% PPV AUC=0.89 AlloHeme ROC curve
Page 24
AlloHeme Positive Signal Occurred a Median 41 Days Before Clinical Relapse Relapses with AlloHeme Positive (n=34) Lead time Median (IQR) 41 (19 – 85) Lead Time Mean ± SD 101 ± 153 Median: 41 days Note: No statistical difference was observed between lead time in AML and MDS cohorts
Page 25
strata Sub-group N total N relapse Sensitivity Specificity PPV NPV AUC P sens P spec Disease Group (AML vs MDS) AML 114 27 0.85 0.92 0.77 0.95 0.89 1 1 MDS 44 13 0.85 0.94 0.85 0.94 0.89 Donor Type Related 55 15 0.87 0.93 0.81 0.95 0.90 1 1 Unrelated 103 25 0.84 0.92 0.78 0.95 0.88 Conditioning Regimen Myeloablative 64 16 0.75 0.92 0.75 0.92 0.83 0.20 1 RIC / Non Myeloablative 94 24 0.92 0.93 0.82 0.97 0.92 Disease Risk Index (DRI) Low or Intermediate 89 16 0.81 0.95 0.77 0.96 0.88 0.67 0.30 High or Very High 69 24 0.88 0.89 0.81 0.93 0.88 Pre-transplant MRD Result Positive 49 15 0.93 0.88 0.78 0.97 0.91 0.60 0.43 Negative 86 16 0.81 0.94 0.77 0.96 0.88 Graft Type PBSC 144 34 0.85 0.92 0.76 0.95 0.89 1 1 Bone marrow 13 5 0.8 1 1 0.89 0.90 GVHD Prophylaxis PTCy 74 22 0.82 0.94 0.86 0.93 0.88 0.68 0.73 All Other 82 17 0.88 0.91 0.71 0.97 0.90 AlloHeme performance is consistent across subgroups
Page 26
*Calculated at either 1% or 5% iMC (STR-PCR) and 1% iMC (qPCR, NGS) in any whole blood, BM, or cell subtype as reported by each participating site; based on available data set on Jan 15 th, 2026 **modeled with CD33 iMC using NGS- based Chimerism assay at 1% cutoff #Statistical significance p<0.05 as compared to AlloHeme AlloHeme has significantly higher sensitivity and longer lead time in detecting relapse compared to real-world chimerism testing Test N Total N Relapse Tests per patient (Median IQR) Sensitivity Specificity PPV NPV AUC Lead time to Relapse (Median IQR) AlloHeme 158 40 11 (8-12) 0.85 0.92 0.79 0.95 0.89 41 (19 – 85) Real World Chimerism* 151 37 5 (3-6) 0.60# 0.86 0.58# 0.87# 0.73# 0 (0 – 80)# NGS- Chimerism Modeled** (at 1% cutoff) 158 40 11 (8-12) 0.53 # 0.93 0.72 0.85 # 0.73 # 16 (1 – 37)#
Page 27
Test Total (n) Relapse (n) Tests per patient (Median IQR) Sensitivity Specificity PPV NPV AUC Lead time to Relapse (Median IQR) AlloHeme 158 40 11 (8-12) 0.85 0.92 0.79 0.95 0.89 41 (19 – 85) BM MFC- MRD* 106 28 3 (2-4) 0.54# 0.92 0.71 0.85# 0.73# 0 (0 – 0) # Mol-MRD* 75 21 2 (1-3) 0.48# 0.91 0.67 0.82# 0.69# 0 (0 – 88) MRD (any method – MFC+Mol) 106 28 5 (3-6) 0.57# 0.90 0.67 0.85# 0.73# 0 (0 – 18) # AlloHeme showed a superior sensitivity, NPV and improved lead time compared to real-world MRD testing in ACROBAT *MFC-MRD and Molecular MRD (PCR or NGS) tests were performed at the participating sites as per their established protocol or treating physician’s discretion; based on available data set on Jan 15th, 2026 #Statistical significance p<0.05 as compared to AlloHeme
Page 28
Case study from ACROBAT Days post transplant to clinical relapse 990 - MFC-MRD Mol-MRD (BM) - 54 + +AlloHeme Test Results +Mol-MRD (BM) + 45 Days Lead Time 32 43 -STR-PCR (BM) - -FISH (PB) Relapse (8% blasts per IHC) • 77yo Female • AML with minimal differentiation (FAB M0). ELN 2017 – adverse risk. FISH: -5, -17/abn(17p); Mol: DNMT3A, TP53, NF1 • Disease status: CR MRD+ before HCT • Donor: MUD, Male • Conditioning: Non-myeloablative • GVHD ppx: PTCy/Tac/MMF
Page 29
Conclusions 1. AlloHeme is a blood-based, NGS-driven, multi-analyte test powered by AI for early and accurate relapse detection in post -HCT AML and MDS patients. 2. ACROBAT 2-year follow up shows strong performance in relapse detection: AUC 89%, Sensitivity 85%, Specificity 92%, NPV 95% and PPV 79%. 3. In relapsed patients, AlloHeme provided a median lead time of 41 days (IQR 19 -85) before clinical relapse. 4. AlloHeme outperformed all real -world chimerism, MFC -MRD, and Molecular MRD methods used as standard of care at participating sites. 5. ACROBAT results suggest that blood -based AlloHeme monitoring offers a simple, effective strategy for identifying relapse risk and enabling early intervention.
Page 30
30 John Hanna President & Chief Executive Officer
Page 31
Allogeneic HCT is a Growing Market 2030 Projected AML & MDS Incidence and Estimated Proportion Eligible for HCT Transplant Growth Drivers: Growing AML & MDS population Increasing referrals for Cell Therapy Expanding donor options Improved overall survival outcomes https://seer.cancer.gov/statfacts/html/amyl.html, Transplant Data based on HRSA Reported from CIBMTR Registry (2019-2023), Company Data on File TAM Est. ~$1Bn AML HCT Eligible 16,500 AML Non-HCT Eligible 7,000 MDS Non- HCT Eligible 6,000 MDS HCT Eligible 5,000
Page 32
AlloHeme Launch Timeline Planned path to commercialization & revenue contribution 2026 2027 2028 • ACROBAT Publication Submission • CLIA Readiness • Commercial Launch • Coverage Submission • Medicare Coverage Est. • Revenue Contribution
Page 33
33 Total Solutions Strategy Cell therapy expected to integrate seamlessly into the comprehensive, end-to-end strategy employed in solid organ transplantation Pre-cell therapy Ongoing testing, medication, and monitoring for graft health Cell Therapy Relapse Detection & Therapy Monitoring Testing Services Personalized Patient and Transplant/Cell Therapy Care Center Services Pharmacy Services, Patient Care Digital Solutions Patient Journey Pre-Transplant Peri-Transplant Post-Transplant Lab Products – HLA Kits CareDx Solutions Cell therapy
Page 34
© 2025 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved. VXXX-XXX-XXXX X-vX. Effective 2025-XX. Thank you.
Page 35
© 2025 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved. VXXX-XXX-XXXX X-vX. Effective 2025-XX. Q&A